CCME Global Ltd
- Market cap
- ₹ 137 Cr.
- P/E
- 66.4x
- P/B
- 3.59x
- 52-week range
- 26.41 – 184.9
- ROE
- −3%
- ROCE
- −2.9%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Biotechnology
- Listed on
- BSE
About
Genesis IBRC India Limited is an India-based biotechnology company. The Company is focused on developing and delivering microbial and antimicrobial products and services. The Company is involved in the manufacturing and marketing a range of specialties in various fields of aquaculture, agriculture, poultry and animal husbandry.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Biotechnology: 6 companies →CCME Global Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)66.4 against a typical 64.5: pricier than most peers (1st = cheapest).4th of 6
- Share price, 3 months−72.4% against a typical −13.2%.5th of 5
- Size₹ 136.7 Cr. market value against a typical ₹ 82.4 Cr. (1st = largest).3rd of 6
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating Profit | −0 | −0 | −4 | −0 | 4 | −0 | −0 | −0 | −0 | −0 | −1 | −0 |
| OPM % | — | — | — | — | 99.5% | — | — | — | — | — | −1,250% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | −4 | −0 | 4 | −0 | −0 | −0 | −0 | −0 | −1 | −0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0 | −0 | −4 | −0 | 4 | −0 | −0 | −0 | −0 | −0 | −1 | −0 |
| EPS in Rs | −0.02 | −0.02 | −2.84 | −0.08 | 2.81 | −0.02 | −0.02 | −0.09 | −0.05 | −0.02 | −0.11 | −0.06 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −99%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −124%
- 10 Years
- 13%
- 5 Years
- 50%
- 3 Years
- 71%
- TTM
- —
- 10 Years
- −2%
- 5 Years
- −2%
- 3 Years
- −3%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| CCME Global Ltd | ₹ 31.93 | ₹ 137 Cr. | 66.4x | 3.6x | −3% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.6x | 5.6x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 87x | 13.6x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.7x | 19.7x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 22.3x | 4.5x | — | 15.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.4x | 3.4x | — | 11.9% |
Management
- Ravindranath Rajaram
- Chief Financial Officer
- Garima Garg
- Compliance Officer, Company Secretary
- Poonam Chaturvedi
- Managing Director, Additional Director
Prices are delayed and for information only. Nothing on this page is investment advice.